Nature Reviews Rheumatology

Article	Citations
No benefit from adding MTX to ustekinumab	525
Bimekizumab effective across the axSpA spectrum	455
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	342
Genome-wide mutagenesis reported in systemic sclerosis	302
The role of the patient in rheumatology	277
Reply to ‘Potential benefit of anticoagulation in Behçet syndrome’	232
A role for TGFβ and EBV in MIS-C pathogenesis	218
Rheumatic diseases on the rise	199
Osteoarthritis as a systemic disease	181
Biological and clinical roles of IL-18 in inflammatory diseases	180
Towards better management of sterile bone inflammation	168
New drug formulation reduces bone loss	162
To choose or not? The value of discrete-choice experiments in rheumatology	160
The value of comparative efficacy studies in informing rheumatology guidelines	160
The 2022 ACR vaccination guideline: a call-to-action	157
Appraising the evolving landscape of protease inhibition in osteoarthritis	150
MIS-C: myths have been debunked, but mysteries remain	150
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	146
FOXP3 splice variant is associated with autoimmune disease	137
Down syndrome: insights into autoimmune mechanisms	135
Inflammation across tissues: can shared cell biology help design smarter trials?	131
Urchin-like nanoparticles for miRNA therapy of OA	131
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	126
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	122
Low-dose glucocorticoids benefit seniors with RA	120

Co-trimoxazole reduces mortality in anti-MDA5-DM	119
Immune reset and immune retune: approaching cure?	114
Fibroblast TGFβ drives treatment-refractory RA	113
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	108
Wnt-induced IGF1 drives OA	108
A direct link between SARS-CoV-2 and bone loss	108
COPA syndrome spans multiple organs but is defined by STING in the lung	108
Author Correction: Proposals for the rheumatological use of JAK inhibitors	104
Calprotectin tracks tocilizumab-treated RA	100
Fumarate drives interferon release in systemic sclerosis monocytes	99
S100A4 inhibition targets fibrosis in SSc	95
Pain in systemic lupus erythematosus: emerging insights and paradigms	95
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	91
Low back pain is a growing concern	90
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	87
Rheumatic diseases and metabolism: where centre and periphery meet	85
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	80
Guiding ILD management in systemic autoimmune rheumatic diseases	79
Rheumatology in the digital health era: status quo and quo vadis?	79
Targeting the IVD clock to halt degeneration	76
Which DMARD for ICI-associated arthritis?	75
Phase III trial of telitacicept in SLE	71
A path towards personalized medicine for autoinflammatory and related diseases	68
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	66
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	66
Cell-free DNA fragmentation signatures link cancer and autoimmunity	66
Erosive cargo from synovial fibroblasts	65
Insights into IVDD pathogenesis in 2024	62
ERAP1 and the return of the UPR in ankylosing spondylitis	60
Macrophage-coated nanocarriers for gouty arthritis	59
CAR T cells induce drug-free SLE remission	59
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	58
RA risk from occupational inhalation	58
Blocking CDK7 attenuates inflammatory arthritis	56
Repolarizing macrophages using antagomirs	55
Fibroblast heterogeneity in 2025	55
A critical view of WHO guidelines on management of low back pain	53
All fibroblasts are equal, but some are more equal than others	52
New refinements aim to optimize articular cartilage tissue engineering	50
Two sides of management recommendations for psoriatic arthritis	49
New developments in electronic health record analysis	49
TASL has a key role in SLE	49
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	47
A leading role for interferon as a treatment target in Sjögren syndrome	47
Platelets as drivers of immunothrombosis in rheumatic diseases	47
Profiling joint tissues at single-cell resolution: advances and insights	46
Innate lymphoid cells in rheumatoid arthritis as mediators of pathology and resolution	45
AhR promotes suppressor cell function in Sjögren syndrome	43
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology	43
Unravelling the cellular mechanisms of VEXAS syndrome	43

Reply to ‘Is cam morphology a cause of osteoarthritis?’	43
Piezo1 induces new bone formation in AS	42
Author Correction: Glycobiology of rheumatic diseases	42
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	40
Treg cell-inducing nanoparticles show promise for treating OA	39
Pathogenic antibodies target stromal antigens in RA	38
Metabolic masqueraders of paediatric and adult rheumatic diseases	36
CXCL5 effective in mouse model of SLE	36
APOE in fat pad and synovium contributes to knee OA	34
Fertility, pregnancy and lactation in women with systemic lupus erythematosus	34
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism	34
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	34
Sex- and gender-based personalized medicine in rheumatology	33
Rethinking early-stage knee osteoarthritis beyond radiography	33
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	33
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies	33
Shifting the SLE management paradigm: challenges and implications	32
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	31
STING-driven necroptosis linked to autoinflammatory disease	30
Senotherapeutics suppress disc degeneration	30
BiTE therapy for rheumatic diseases	29
In vivo CAR-T cell engineering in refractory SLE	29
Post-transcriptional checkpoints in autoimmunity	29
Location-specific treatment of chronic inflammatory joint disease	29
Parathyroid hormone receptor agonists in the management of osteoporosis	28
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	27
Critical appraisal of serum urate targets in the management of gout	27
FABP4 exacerbates RA	26
Multi-omics reveals distinct MPA subtypes	26
Detachment promotes RA synovial fibroblast survival and invasiveness	26
COVID-19 linked to rise in anti-MDA5 autoimmunity	25
Adropin inhibits fibrosis in SSc	25
State-of-the-art evidence in the treatment of systemic sclerosis	24
Engineered sialylated IgG1 Fc as a dose-sparing alternative to IVIG	24
Complement therapeutics are coming of age in rheumatology	24
Notch signalling mediates OA pain in mice	24
Busting the myth of methotrexate chronic hepatotoxicity	24
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	23
The potential contribution of in silico studies to improved treatment of osteoarthritis	23
Citrulline immunity in RA: CD8+ T cells enter the scene	23
Synovial fluid as a complex molecular pool contributing to knee osteoarthritis	22
Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells	22
Identifying fibromyalgia phenotypes based on psychological symptom burden	20
Treatment of non-systemic juvenile idiopathic arthritis	20
What rheumatology can learn from oncology: a patient’s perspective	20
Update on the pathophysiology and treatment of primary Sjögren syndrome	19
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	19
Undiagnosed axSpA is prevalent in IBD	18
The immune health metric as an indicator of health and disease	18
Glycosylation switch in synovial fibroblasts promotes ECM degradation	18
The PU.1– IL-9 axis in TH9 cells promotes RA	18
Combination therapy for Behçet uveitis	17
Primary care rheumatology: towards sustainable development in health	17
Bone-modifying drugs slow OA progression	17
UNC93B1 variants promote SLE via TLR activation	17
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk	17
Lupus ABC spearheading a new era of collaboration to advance lupus drug development	16
Shedding light onto the immunometabolic effects of glucocorticoids	16
Advances in understanding preclinical rheumatoid arthritis and prospects for prevention	16
SIX1 and PAI-1 emerge as therapeutic targets in systemic sclerosis	16
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy	15
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions	15
More than a leaky gut: how gut priming shapes arthritis	14
Reversal of inflammatory priming prevents arthritic flares	14
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	14
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?	13
Paediatric glucocorticoid toxicity index: new possibilities in assessment	13
T cell differentiation in Sjögren syndrome is regulated by TOX	13
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	12
Disease stratification in GCA and PMR: state of the art and future perspectives	12
New guide calls for interdisciplinary approach to TMJ arthritis symptoms	12
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition	12
Advances in the calculation of minimal important change estimates for patient-reported outcome measures	12
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies	12
Global epidemiology of spondyloarthritis	12
Neurodevelopmental comorbidities in juvenile systemic autoimmune and autoinflammatory diseases	12
Evidence-Based Guideline for the management of osteoporosis in men	12
PPM1A: TGFβ regulator and therapeutic target in OA	11
Synovial fibroblast-mediated neovascularization in RA	11
Pregnancy outcomes improving in axSpA	11

CD38hiCD8+ T cells characterize ICI-mediated arthritis	11
Macrophages hit a nerve in painful joint venture	11
Treat-to-target or treat-to-dissolve strategy to improve gout treatment	11
Real-world data provide insights into PsA treatment patterns	11
Age-related mechanisms in the context of rheumatic disease	10
When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy	10
Bridging the gap: combining treat-to-target and difficult-to-treat strategies in the management of rheumatoid arthritis	10
Gut T cells help mediate fracture healing	10
The apprehension of seronegative rheumatoid arthritis	10
Imaging in inflammatory arthritis: progress towards precision medicine	10
Benralizumab noninferior to mepolizumab for EGPA	9
Annexin A1 could help prevent periprosthetic bone loss	9
PJP prophylaxis with rituximab	9
ZEB2 promotes formation of age-related B cells	8
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration	8
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone	8
TGFβ priming promotes TNF-induced bone erosion: a promising new target in RA?	8
Author Correction: New genes, pathways and therapeutic targets in autoinflammatory diseases	8
SGLT2 inhibitors reduce risk of autoimmune disease	8
New guideline for integrative approaches to RA management	8
Treat-to-target in Behçet syndrome	8
Optimizing methotrexate withdrawal during COVID vaccination	8
Relapsing polychondritis: clinical updates and new differential diagnoses	7
Immunogenic Xist ribonucleoproteins drive sex-biased autoimmunity	7
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout	7
High risk of autoimmune diseases after COVID-19	7
Reply to: Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups	6
New screening tool developed to aid diagnosis of axial PsA	6
Lupus nephritis-related chronic kidney disease	6
Clonal dominance: mutations in VEXAS syndrome take advantage of inflammation	6
How muscle influences bone health	6
ETS1 implicated in polarization of tissue-destructive fibroblasts	6
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity	6
Two subsets of TPH cells with distinct functions in RA	6
JAK inhibitors improve RA pain	6
Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis	6
Collagen-binding antibody prevents arthritis	5
Inborn errors of immunity and AAV: a complex picture	5
PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease	5
The future of autologous stem cell transplantation in systemic sclerosis	5
Limitations of the updated EULAR recommendations for osteoarthritis	5
ExTH17 cells maintain chronic inflammation in RA	5
The peculiar features, diversity and impact of citrulline-reactive autoantibodies	5
Mechanism of B cell survival in lupus nephritis	5
Pregnancy outcomes in SLE have not improved	5
Sarcoidosis: can tofacitinib slay the dragon?	5
Understanding synovial cell diversity in post-traumatic OA	5
Targeting UHRF1 in RA	4
Sex and gender differences in rheumatology: clinical impact and future directions	4
Integrin signalling in joint development, homeostasis and osteoarthritis	4
Is X chromosome inactivation a cause or effect of SLE?	4
A comprehensive guide for managing the reproductive health of patients with vasculitis	4
Treating inflammatory arthritis in individuals with concomitant cancer	4
Reply to: Hypothetical model ignores many important pathophysiologic mechanisms in fibromyalgia	4
T cells in Sjögren disease	4
Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress	4
The role of mitochondria in rheumatic diseases	4
Integrin-mediated ILC2 adhesion protects against lupus nephritis	4
Publisher Correction: IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	4
Fibroblasts in immune responses, inflammatory diseases and therapeutic implications	4
Sex and gender matter for TNF inhibitor therapy in RA	4
PR3 triggers granuloma formation in GPA	4
Advances in cartilage imaging techniques	4
The therapeutic potential of immunoengineering for systemic autoimmunity	4
VEXAS syndrome more common than originally thought?	4
A basket genetic trial of the vasculitides	4
Joint location matters for TNF inhibitor treatment in PsA	4
Breaking research silos to achieve equitable precision medicine in rheumatology	4
Pentose phosphate pathway metabolite restores T cell balance in SLE	4
A subset of ITGA5+ synovial fibroblasts alter the inflammatory niche in RA	3
Hypoxia-modifying hydrogel supports stem cells for joint repair	3
Author Correction: Parathyroid hormone receptor agonists in the management of osteoporosis	3
Molecular biomarker approaches to prevention of post-traumatic osteoarthritis	3
Mannosylation is a cause and target in lupus nephritis	3
CXCL7 promotes bone erosion in RA	3
Mito+ RBCs prompt IFN and IL-1β release by SLE monocytes	3
Insights into the pathogenesis of childhood-onset SLE in the past decade	3
Genetically transitional disease: conceptual understanding and applicability to rheumatic disease	3
New evidence for the ‘cusp theory’ to explain HLA associations in SLE	3
Reply to ‘Inborn errors of immunity and AAV: a complex picture’	3
Novel approach mitigates immunogenicity of uricase treatment	3
Author Correction: Inflammation and pain as interconnected targets in axial spondyloarthritis	3
Transitional care: time for a rethink?	3
A safe and effective treatment for MAS	3
Antigen-specific immunotherapies for autoimmune disease	3
Are the origins of adult arthritis seeded during embryonic development?	3
Sex- and gender-related differences in psoriatic arthritis	3
A roadmap for delivering a human musculoskeletal cell atlas	3
Understanding rheumatic disease through continuous cell state analysis	3
Immune tolerance of citrullinated peptides	3
Rethinking antiphospholipid syndrome to guide future management and research	3
How does citrullination contribute to RA autoantibody development?	3
Pre-RA autoantibodies recognize arthritogenic gut bacterium	3
Global epidemiology of rheumatoid arthritis	3
Deep learning in rheumatological image interpretation	3